Enanta Pharmaceuticals to Present at the Baird 2019 Global Healthcare Conference

Enanta Pharmaceuticals, Inc. ENTA, a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat presentation at the following investor conference:

September 4, 12:50 p.m. ET; Baird 2019 Global Healthcare Conference, New York

A live webcast of the presentation will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for approximately 30 days.

About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta's research efforts are ongoing and have generated drug candidates currently in clinical development for each of the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), and hepatitis B virus (HBV).

Enanta's research and development activities are funded by royalties from HCV products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is now sold by AbbVie in numerous countries as part of its 8-week, pan-genotypic treatment for the majority of patients with chronic hepatitis C virus (HCV) infection. This leading HCV regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). For more information, please visit www.enanta.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190821005003/en/